DYN: Dyne Therapeutics Inc

DYN News

• Investing 15:30 Avidity Biosciences stock soars on Novartis takeover approach report
• Investing 15:11 Dyne Therapeutics stock gains as DYNE-251 receives FDA breakthrough designation
• Investing 13:10 Dyne Therapeutics stock rises after FDA grants breakthrough therapy status
• Zacks 13:55 Does Dyne Therapeutics (DYN) Have the Potential to Rally 285.57% as Wall Street Analysts Expect?
• Investing 21:31 Stifel lowers Dyne Therapeutics stock price target to $36 on endpoint changes
• Benzinga 16:51 These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss - Dyne Therapeutics (NASDAQ:DYN)
• The Motley Fool 01:33 Dyne Reports Wider Loss in Fiscal Q2
• Investing 21:00 Dyne Therapeutics extends cash runway as it advances key drug programs
• Investing 12:34 Bernstein lowers Dyne Therapeutics stock price target on equity raise
• Benzinga 13:00 Tesla, Progress Software, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - AeroVironment (NASDAQ:AVAV), Dyne Therapeutics (NASDAQ:DYN)
• Investing 11:38 Tesla, AeroVironment and Progress Software fall premarket; MSC Industrial rises
• Benzinga 09:23 Why Thumzup Media Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Argo Blockchain (NASDAQ:ARBK), Applied DNA Sciences (NASDAQ:APDN)
• Investing 20:26 Dyne Therapeutics stock falls after announcing $200 million share offering
• Investing 20:09 Dyne Therapeutics secures $275 million loan facility from Hercules Capital
• Investing 20:58 Jones Trading initiates Dyne Therapeutics stock with buy rating
• Investing 10:03 Avidity, Dyne get Bernstein ratings as oligonucleotide muscle trials advance
• Seeking Alpha 15:08 Dyne Therapeutics: Emergence As A Superior DM1/DMD Player Warrants Rating Upgrade (DYN)
• Investing 11:31 H.C. Wainwright reiterates buy rating on Dyne Therapeutics stock
• Benzinga 14:56 Why Is Dyne Therapeutics Stock Trading Lower On Tuesday? - Dyne Therapeutics (NASDAQ:DYN)
• Investing 11:49 Dyne Therapeutics stock falls after updated plan for accelerated approval in DM1
• Investing 11:05 Dyne’s DM1 treatment receives FDA breakthrough designation
• Investing 20:20 Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET
• Investing 13:15 Raymond James bullish on biotech firms on favorable valuation
• Investing 13:42 Oppenheimer assumes Dyne Therapeutics stock at outperform, PT $34